No profile data available.
Exicure, Inc. (XCUR) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Redwood City, United States, with about 1 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$4.95 million. Its market capitalization was $6.87 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. , Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure reported $0 in revenue for fiscal year 2025, down 100.0% from $500,000 in fiscal year 2024.
$6.87 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Hepion Pharmaceuticals, Inc. (HEPA), Chemomab Therapeutics Ltd. (CMMB), MetaVia Inc. (MTVA).